MedDataX Logo

Observational Study in Patients With HIV Infection Type 1 After Switching to a Viramune®-Containing Therapy Regimen

NCT ID: NCT02191332

Last Updated: 2014-07-16

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

147 participants

Study Classification

OBSERVATIONAL

Study Start Date

1999-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Observational study to collect data on maintaining anti-retroviral activity (quantitative HIV RNA determination) and immunological activity (CD4 cells) despite switching from protease inhibitor to nonnucleoside reverse transcriptase inhibitor (NNRTI) (Viramune®).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Long-term Study in Patients Under Anti-retroviral Combination Therapy Switching to Viramune®

NCT02191293

HIV Infections
COMPLETED

Observational Study With Antiretroviral Treated Patients Switching to Nevirapine Plus Two Nucleoside Reverse Transcriptase Inhibitor (NRTI) Regimens

NCT02191319

HIV Infections
COMPLETED

Impact of Switching to NNRTI-based Therapy on the Quality of Life of HIV-infected Patients With Virological Suppression

NCT02191202

HIV Infections
COMPLETED

Non-interventional Observational Study With Viramune® in HIV to Evaluate Gender Specific Data

NCT01134939

HIV Infections
COMPLETED

Tipranavir in Patients With Progressive, Systemic HIV-1 Disease Who Have Failed or Are Intolerant to Currently Approved Treatments for HIV Infection

NCT00062660

HIV Infections
APPROVED_FOR_MARKETING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HIV Infections

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Viramune

Viramune

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Viramune

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult male or female patients with HIV type 1 infection

Exclusion Criteria

* Counter-indications according to summary of product characteristics (SPC) for Viramune tablets
* No persons under 18
* Pregnancy and breast-feeding
* Use of oral contraceptives
* Use of drugs affecting CYP450 3A metabolism
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Boehringer Ingelheim

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

1100.1305

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

PMS Assessing the Long-term Efficacy and Safety of Nevirapine Therapy (Combined With Other ARV Drugs) in HIV-1 Positive Patients in Daily Clinical Practice.
NCT00736502 COMPLETED
Utilization of HIV Drug Resistance Testing in Treatment Experienced Patients (UTILIZE Study)
NCT00615563 COMPLETED
Observational Study of HIV-Infected Subjects With X4-Tropic or Non-Phenotypeable Virus
NCT00321438 TERMINATED
A Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIV
NCT07053384 RECRUITING PHASE1
A Study to Evaluate Virologic Response in Participants Newly Diagnosed With HIV-1
NCT04147325 COMPLETED
Safety and Effect on HIV Transcription of Vorinostat in Patients Receiving Suppressive Combination Anti-retroviral Therapy
NCT01365065 UNKNOWN PHASE2
Dynamics of Drug Resistance-associated Mutations in HIV-1 DNA Reverse Transcriptase Clearance During Effective Antiretroviral Therapy
NCT04448158 COMPLETED
A Long-term Follow-up of the HIV-NAT Cohort
NCT00411983 RECRUITING
Phase 3 Open-Label Study to Evaluate Switching From Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) Plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive Adults
NCT01968551 COMPLETED PHASE3
Immunological and Viral Response to Antiretrovirals in HIV Patients With CD4 Cell Count Below 100
NCT00385957 COMPLETED PHASE4
HIV Switch Trial in Experienced Patients With Multiple Class Resistance Including NNRTI Resistance
NCT04334551 UNKNOWN PHASE4
Structured Treatment Interruption for HIV Patients With Virologic Failure
NCT00188851 COMPLETED NA
Once-daily Antiretroviral Therapy in HIV-1 Infected Patients With CD4+ Cell Counts Below 100 Cells/Mcl
NCT00532168 COMPLETED PHASE4
Impact of Extremely Early Antiretroviral Therapy to Reduce VIral REservoir and Induce Functional CURE of HIV-1 Infection
NCT02588820 UNKNOWN PHASE3
Open-Label Multi-Centre Randomised Switch Study to Evaluate Virological Efficacy Over 96Weeks Of 2-Drug Therapy With Dolutegravir(DTG)/Rilpivirine(RPV) Fixed Dose Combination(FDC) in Antiretroviral Treatment-Experienced HIV-1 Infected Subjects Virologically Suppressed With NNRTI Mutation K103N
NCT05349838 COMPLETED PHASE3
Second-line Therapy Antiretroviral in Patients Who Failed Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) - Based Regimens
NCT00627055 COMPLETED PHASE4
Study of Protease Inhibitor Regimen Switch in HIV-1 Infected Patients With Undetectable Viral Load to Prove the Non-inferiority of Once Daily Dose Regimen Versus the Current Twice Daily Regimen to Maintain the Viral Load Under the Limit of Detection.
NCT00849160 COMPLETED PHASE3
Immune and Viral Status of HIV-Infected Patients After Stopping Combination Antiretroviral Therapy
NCT00001899 COMPLETED
A Trial With TMC278-TIDP6-C222 for Continued TMC278 Access in Patients Infected With Human Immunodeficiency Virus-1
NCT01266902 COMPLETED PHASE3
CD4 Cell Recovery in HIV-1 Patients Comparing 2 Treatment Regimes
NCT00966160 COMPLETED PHASE3
Study to Assess Safety and Activity of Combination Therapy of VRC07-523LS and Vorinostat on HIV-infected Persons
NCT03803605 COMPLETED PHASE1
Registry to Assess Long-term Outcome in HIV Subjects Who Participated in Phase 2 and 3 Clinical Trials Involving Vicriviroc (Study P04999)
NCT00705419 COMPLETED
DORAvirine Versus DOlutegravir Based Antiretroviral Regimens in Treatment-naïve People Living With HIV-1 Infection
NCT06203132 RECRUITING PHASE3
An Observational Study of Induction Therapy With Fuzeon (Enfuvirtide) in Combination With Antiretroviral Drugs in Patients With HIV-1 Infection
NCT01902615 COMPLETED
DOR/TDF/3TC Switch With M184V/I in People With Controlled HIV (Drive Off-Road)
NCT06034938 RECRUITING PHASE2